Search
Takeda Pharmaceutical Co Ltd
TAKAdd to Watchlist
15.720USD
-0.120-0.76%
Close 06/24, 16:00（ET）Quotes delayed by 15 min
50.21BMarket Cap
40.98P/E TTM
More Details of Takeda Pharmaceutical Co Ltd Company
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
Takeda Pharmaceutical Co Ltd Info
Ticker SymbolTAK
Company nameTakeda Pharmaceutical Co Ltd
IPO dateJun 21, 2085
CEOWeber (Christophe)
Number of employees47455
Security typeDepository Receipt
Fiscal year-endJun 21
Address4F
CityCHUO-KU
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryJapan
Postal code103-8668
Phone81332782111
Websitehttps://www.takeda.com/
Ticker SymbolTAK
IPO dateJun 21, 2085
CEOWeber (Christophe)
Company Executives of Takeda Pharmaceutical Co Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
7.60K
--
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Dr. Andrew S. Plump, Ph.D.
Dr. Andrew S. Plump, Ph.D.
President of Research & Development, Director
President of Research & Development, Director
--
--
Mr. Tokumasa Takeda
Mr. Tokumasa Takeda
Global Finance Chief Accounting Officer & Corporate Controller
Global Finance Chief Accounting Officer & Corporate Controller
--
--
Mr. Michel Orsinger
Mr. Michel Orsinger
Independent Director
Independent Director
--
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
--
--
Mr. Yoshiaki Fujimori
Mr. Yoshiaki Fujimori
Independent Director
Independent Director
--
--
Mr. Koji Hatsukawa
Mr. Koji Hatsukawa
Independent Director
Independent Director
--
--
Mr. Jean-Luc Butel
Mr. Jean-Luc Butel
Independent Director
Independent Director
--
--
Mr. Ian T. Clark
Mr. Ian T. Clark
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
7.60K
--
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Dr. Andrew S. Plump, Ph.D.
Dr. Andrew S. Plump, Ph.D.
President of Research & Development, Director
President of Research & Development, Director
--
--
Mr. Tokumasa Takeda
Mr. Tokumasa Takeda
Global Finance Chief Accounting Officer & Corporate Controller
Global Finance Chief Accounting Officer & Corporate Controller
--
--
Mr. Michel Orsinger
Mr. Michel Orsinger
Independent Director
Independent Director
--
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Takeda Pharmaceutical Co Ltd?
The top five shareholders of Takeda Pharmaceutical Co Ltd are: Dr. John M. Maraganore, Ph.D.
How many institutions hold shares of Takeda Pharmaceutical Co Ltd (TAK)?
As of 2026Q1, 637 institutions hold shares of Takeda Pharmaceutical Co Ltd, with a combined market value of approximately 85.31M, accounting for 2.70% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -8142483.00.
What is the biggest source of revenue for Takeda Pharmaceutical Co Ltd?
In 2026Q1, the Gastrointestinal diseases business generated the highest revenue for Takeda Pharmaceutical Co Ltd, amounting to 385.81B and accounting for 32.37% of total revenue.
